Mirabegron (trade name: Betmiga) has been approved since December 2012 for the treatment of adults with overactive bladder. The Institute for Quality and Efficiency in Health Care (IQWiG) has pursuant to the Pharmaceutical Market Restructuring Act (AMNOG) determined whether this new drug offers an additional clinical benefit over appropriate comparatoe therapy as determined by the Federal Joint Committee (G-BA).

Mirabegron shows an advantage in terms of side effects, compared with tolterodine, dry mouth occurs less frequently. With regard to mortality, morbidity and quality of life endpoints, no added value can be ascertained. Because the manufacturer's dossier for the total population of the relevant patient population, data on morbidity criteria such as incontinence and urge incontinence were missing, a final assessment of the ositive and negative effects for added value is not possible. The overall picture, therefore, is that an additional benefit for mirabegron is not occupied.

Fore more details, go to: https://www.iqwig.de/de/presse/pressemitteilungen/pressemitteilungen/mirabegron-bei-uberaktiver-blase-zusatznutzen-nicht-belegt.6264.html?&et_cid=4&et_lid=%25208 [German]